BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ardian Completes $47 Million Financing Led by Medtronic, Inc. (MDT) to Develop Hypertension Treatment


3/23/2009 7:22:06 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Ardian, Inc., developer of a breakthrough catheter-based medical device to treat hypertension, announced today that Medtronic, Inc. (NYSE:MDT - News), one of the world's leading medical technology companies, has led a $47 million financing of the company. Joining Medtronic are Ardian's three existing investors: Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners, as well as new investor Emergent Medical Partners.

Hypertension, which affects approximately one-third of the developed world's adult population, significantly increases the risk of heart attack, stroke, heart failure and chronic kidney disease. It is the single most common contributor to death worldwide. Surprisingly, only 35% of hypertensive patients are satisfactorily controlled with medication. A major contributor to the development and perpetuation of hypertension is hyper-activation of the sympathetic nervous system. Ardian’s Symplicity® Catheter System™ disrupts the renal sympathetic nerves by means of a straightforward 40-minute procedure, thereby reducing sympathetic activation and hence blood pressure.

“We are thrilled to have attracted this strong team of investors and appreciate the confidence they have shown in funding the development of this clinically important technology,” said Andrew Cleeland, President and CEO of Ardian. “We are particularly encouraged to have Medtronic as a new partner, and see their investment as a validation of our exceptional early clinical results, as well as the potential of our treatment for such a pervasive and complex disease.”

Commenting on the investment by Emergent Medical Partners, led by Dr. Thomas J. Fogarty, Cleeland said: “Dr Fogarty is a legend in the cardiovascular field, and having him make an investment speaks volumes for the promise of this technology.”

“Closing this financing with such great strategic partners would be impressive in the best of times, and in this difficult financial environment it is even more so," said Mike Carusi, General Partner at Advanced Technology Ventures. “The Board of Directors is very pleased with Ardian’s ongoing evolution and looks forward to continued success.”

Regarding another important milestone for the company, Cleeland noted that Professor Henry Krum of the Alfred Hospital/Monash University in Melbourne, Australia, is to present the early clinical experience with Ardian’s Symplicity® Catheter System™ at the upcoming American College of Cardiology’s Annual Meeting (ACC.09) in Orlando, Florida. This presentation will be part of a late-breaking clinical trials session scheduled for 9:15 am, on March 30, 2009.

About Hypertension

Hypertension (high blood pressure) is the leading attributable cause of death worldwide. In the United States alone, high blood pressure affects approximately 73 million people only two thirds of whom are treated. Close to half of all people with hypertension in treatment are not currently reaching their target blood pressure. Each incremental 20mmHg increase of systolic blood pressure above normal levels is associated with a doubling of cardiovascular mortality over a ten-year period.

About Ardian

Ardian, Inc., headquartered in Palo Alto, California, is a pioneering private, clinical-stage medical device company developing a novel catheter-based treatment for hypertension, chronic kidney disease and heart failure; three interdependent disease states that represent a significant, escalating global health issue. Ardian is the eighth company created by The Foundry, a leading medical device incubator based in Menlo Park, California. For more information about the Symplicity® Catheter System™, Ardian or clinical trials, please visit www.ardian.com.

Contact:

Ardian, Inc. Andrew Cleeland, 650-496-5545 President and CEO info@ardianinc.com or The Gibson Network Tom Gibson, 216-320-1520 (Media) tgibson1@ameritech.net or Kureczka/Martin Associates Ellen M Martin, 510-832-2044 (Media) emm4@pacbell.net

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES